Get started
Work

Myeloablative Autologous Transplantation of CD34 + Selected Hematopoietic Stem Cells (HSCT) vs Monthly Intravenous Cyclophosphamide (CY) for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial

Year: 2017
Type: article
Abstract: Background: Therapeutic options for diffuse cutaneous systemic sclerosis (dcSSc) are limited. The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial was a multicenter study designed to evaluate the long-term benefit of myeloablative autologous HSCT compared to 12 monthly pulses of CY.
DOI: 10.1016/j.bbmt.2017.01.012
Authors: Keith Sullivan, Lynettee Keyes-Elstein, Peter McSweeney, Ashley Pinckney, Beverly Welch, Maureen Mayes, Richard Nash, Leslie Crofford, Sharon Castina, Linda M. Griffith, Ellen Goldmuntz, Daniel Furst
Institutions: Duke Medical Center, Rho (United States), Colorado Blood Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Vanderbilt University, University of California, Los Angeles
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2590620761
FWCI: 2.155
Cites:
Cited by: 17
Related to: 10